<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:tcas="http:///uima/tcas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:cas="http:///uima/cas.ecore" xmlns:types="http:///fr/inra/maiage/bibliome/alvisnlp/bibliomefactory/modules/uima/types.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="8" sofa="1" begin="0" end="1610" language="x-unspecified"/>
    <types:DocumentProxy xmi:id="13" sofa="1" id="entities.read.Corpuschoice.WOKread.readWoKcorpus132" features="18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90 93 96 99 102 105 108 111 114 117 120 123 126 129 132 135 138 141 144 147 150 153 156 159 162 165 168 171 174 177 180 183 186 189 192 195 198 201 204 207 210" sections="280 298"/>
    <cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Molecular farming on rescue of pharma industry for next generationsRecombinant proteins expressed in plants have been emerged as a novel branch of the biopharmaceutical industry, offering practical and safety advantages over traditional approaches. Cultivable in various platforms (i.e. open field, greenhouses or bioreactors), plants hold great potential to produce different types of therapeutic proteins with reduced risks of contamination with human and animal pathogens. To maximize the yield and quality of plant-made pharmaceuticals, crucial factors should be taken into account, including host plants, expression cassettes, subcellular localization, post-translational modifications, and protein extraction and purification methods. DNA technology and genetic transformation methods have also contributed to great parts with substantial improvements. To play their proper function and stability, proteins require multiple post-translational modifications such as glycosylation. Intensive glycoengineering research has been performed to reduce the immunogenicity of recombinant proteins produced in plants. Important strategies have also been developed to minimize the proteolysis effects and enhance protein accumulation. With growing human population and new epidemic threats, the need for new medications will be paramount so that the traditional pharmaceutical industry will not be alone to answer medication demands for upcoming generations. Here, we review several aspects of plant molecular pharming and outline some important challenges that hamper these ambitious biotechnological developments."/>
    <types:FeatureProxy xmi:id="18" key="source" value="wok"/>
    <types:FeatureProxy xmi:id="21" key="url" value="https://doi.org/"/>
    <types:FeatureProxy xmi:id="24" key="url" value="https://doi.org/10.3109/07388551.2015.1049934"/>
    <types:FeatureProxy xmi:id="27" key="publication-type" value="J"/>
    <types:FeatureProxy xmi:id="30" key="AU" value="Moustafa, K"/>
    <types:FeatureProxy xmi:id="33" key="AU" value="Makhzoum, A"/>
    <types:FeatureProxy xmi:id="36" key="AU" value="Tremouillaux-Guiller, J"/>
    <types:FeatureProxy xmi:id="39" key="AF" value="Moustafa, Khaled"/>
    <types:FeatureProxy xmi:id="42" key="AF" value="Makhzoum, Abdullah"/>
    <types:FeatureProxy xmi:id="45" key="AF" value="Tremouillaux-Guiller, Jocelyne"/>
    <types:FeatureProxy xmi:id="48" key="SO" value="CRITICAL REVIEWS IN BIOTECHNOLOGY"/>
    <types:FeatureProxy xmi:id="51" key="LA" value="English"/>
    <types:FeatureProxy xmi:id="54" key="DT" value="Review"/>
    <types:FeatureProxy xmi:id="57" key="DE" value="Molecular farming"/>
    <types:FeatureProxy xmi:id="60" key="DE" value="molecular farming applications"/>
    <types:FeatureProxy xmi:id="63" key="DE" value="molecular pharming"/>
    <types:FeatureProxy xmi:id="66" key="DE" value="plant made pharmaceuticals"/>
    <types:FeatureProxy xmi:id="69" key="DE" value="plant molecular farming"/>
    <types:FeatureProxy xmi:id="72" key="DE" value="protein stability"/>
    <types:FeatureProxy xmi:id="75" key="DE" value="recombinant proteins"/>
    <types:FeatureProxy xmi:id="78" key="DE" value="therapeutic drug"/>
    <types:FeatureProxy xmi:id="81" key="ID" value="ARABIDOPSIS-THALIANA SEEDS"/>
    <types:FeatureProxy xmi:id="84" key="ID" value="PLANT-MADE PHARMACEUTICALS"/>
    <types:FeatureProxy xmi:id="87" key="ID" value="VIRUS-LIKE"/>
    <types:FeatureProxy xmi:id="90" key="ID" value="PARTICLES"/>
    <types:FeatureProxy xmi:id="93" key="ID" value="HUMAN SERUM-ALBUMIN"/>
    <types:FeatureProxy xmi:id="96" key="ID" value="RECOMBINANT PROTEINS"/>
    <types:FeatureProxy xmi:id="99" key="ID" value="TRANSGENIC PLANTS"/>
    <types:FeatureProxy xmi:id="102" key="ID" value="TOBACCO CHLOROPLASTS"/>
    <types:FeatureProxy xmi:id="105" key="ID" value="NICOTIANA-TABACUM"/>
    <types:FeatureProxy xmi:id="108" key="ID" value="PRODUCTION PLATFORMS"/>
    <types:FeatureProxy xmi:id="111" key="ID" value="THERAPEUTIC PROTEIN"/>
    <types:FeatureProxy xmi:id="114" key="ID" value="entities.read.Corpuschoice.WOKread.readWoKcorpus132"/>
    <types:FeatureProxy xmi:id="117" key="C1" value="[Moustafa, Khaled] Conservatoire Natl Arts &amp; Metiers, Paris, France."/>
    <types:FeatureProxy xmi:id="120" key="C1" value="[Makhzoum, Abdullah] Univ Western Ontario, London, ON, Canada."/>
    <types:FeatureProxy xmi:id="123" key="C1" value="[Tremouillaux-Guiller, Jocelyne] Univ Tours, Fac Sci Pharmaceut, Tours, France."/>
    <types:FeatureProxy xmi:id="126" key="RP" value="Moustafa, K (reprint author), Conservatoire Natl Arts &amp; Metiers, Paris, France."/>
    <types:FeatureProxy xmi:id="129" key="EM" value="khaled.moustafa@gmail.com"/>
    <types:FeatureProxy xmi:id="132" key="NR" value="113"/>
    <types:FeatureProxy xmi:id="135" key="TC" value="0"/>
    <types:FeatureProxy xmi:id="138" key="Z9" value="0"/>
    <types:FeatureProxy xmi:id="141" key="U1" value="34"/>
    <types:FeatureProxy xmi:id="144" key="U2" value="34"/>
    <types:FeatureProxy xmi:id="147" key="PU" value="TAYLOR &amp; FRANCIS LTD"/>
    <types:FeatureProxy xmi:id="150" key="PI" value="ABINGDON"/>
    <types:FeatureProxy xmi:id="153" key="PA" value="2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND"/>
    <types:FeatureProxy xmi:id="156" key="SN" value="0738-8551"/>
    <types:FeatureProxy xmi:id="159" key="EI" value="1549-7801"/>
    <types:FeatureProxy xmi:id="162" key="J9" value="CRIT REV BIOTECHNOL"/>
    <types:FeatureProxy xmi:id="165" key="JI" value="Crit. Rev. Biotechnol."/>
    <types:FeatureProxy xmi:id="168" key="PD" value="OCT"/>
    <types:FeatureProxy xmi:id="171" key="PY" value="2016"/>
    <types:FeatureProxy xmi:id="174" key="VL" value="36"/>
    <types:FeatureProxy xmi:id="177" key="IS" value="5"/>
    <types:FeatureProxy xmi:id="180" key="BP" value="840"/>
    <types:FeatureProxy xmi:id="183" key="EP" value="850"/>
    <types:FeatureProxy xmi:id="186" key="DI" value="10.3109/07388551.2015.1049934"/>
    <types:FeatureProxy xmi:id="189" key="PG" value="11"/>
    <types:FeatureProxy xmi:id="192" key="WC" value="Biotechnology &amp; Applied Microbiology"/>
    <types:FeatureProxy xmi:id="195" key="SC" value="Biotechnology &amp; Applied Microbiology"/>
    <types:FeatureProxy xmi:id="198" key="GA" value="DS8TA"/>
    <types:FeatureProxy xmi:id="201" key="UT" value="WOS:000381054700006"/>
    <types:FeatureProxy xmi:id="204" key="PM" value="26042351"/>
    <types:FeatureProxy xmi:id="207" key="identifiant" value="entities.read.Corpuschoice.WOKread.readWoKcorpus132"/>
    <types:FeatureProxy xmi:id="210" key="doi" value="10.3109/07388551.2015.1049934"/>
    <types:SectionProxy xmi:id="280" sofa="1" begin="0" end="67" name="TI" features="288" layers="" relations=""/>
    <types:FeatureProxy xmi:id="288" key="sectionname" value="title"/>
    <types:SectionProxy xmi:id="298" sofa="1" begin="67" end="1610" name="AB" features="306" layers="" relations=""/>
    <types:FeatureProxy xmi:id="306" key="sectionname" value="abstract"/>
    <cas:View sofa="1" members="8 13"/>
</xmi:XMI>
